Anti-Mouse CD4 Antibody (Clone GK1.5) – Purified in vivo GOLD™ Functional Grade

Mouse CTL clone V4

This monoclonal CD4 antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 2-8°C

B
Costim
Depletion
IHC
IP

Rat Anti-Mouse CD4 antibody (Clone GK1.5) recognizes an epitope on Mouse CD4. This monoclonal CD4 antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

CD4 (cluster of differentiation 4) is a glycoprotein expressed on the surface of T helper cells, regulatory T cells, monocytes, macrophages, and dendritic cells. CD4 interacts with class II molecules of the major histocompatibility complex (MHC) enhancing the signal for T-cell activation.⁶

Majority of thymocytes, T cell subset

MHC class II molecule

T cell activation

1.) Ardolino, M. et al. (2018) J Clin Invest. 128(10):4654-4668. PubMed
2.) Schreiber, RD. et al. (2017) Cancer Immunol Res. 5(2):106-117. PubMed
3.) Nicolas, JF. et al. (2002) J Immunol.168(6):3079-87. Article Link
4.) Shin, H. et al. (2018) J Virol. 92(7): e00038-18. PubMed
5.) Chiang, BL. et al. (2001) Immunology. 2001 103(3): 301–309. PubMed
6.) Hendrickson, WA. et al. (1994) Structure 2: 59
7.) Skyberg, J. A. et al. (2020) Infection and Immunity. 88: 5 Journal Link
8.) Raju et al. (2019) Cell Reports. 29:2556–2564 Journal Link
9.) Gubin, M. et al. (2018) Cell. 175(4):1014–1030 Journal Link
10.) Sharma S. et al. (2020) Human Vaccines & Immunotherapeutics 16(9):2196-2203 Journal Link
11.) Hawman DW, et al. (2021) Microorganisms 9(2):279 Journal Link